The only tool to prevent already-COVID positive patients from ending up in the hospital is now even more limited than it was before.
Early reports suggest just one brand of antibody treatments is effective against the rapidly spreading omicron variant. Sotromivab is up to 1,000-times more effective against the dominating strain than the other two brands on the market.
The other brands, previously used to prevent severe illness from other strains, is so ineffective against omicron, providers are being told to stop using them altogether.